NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
Clinical Trials
115 trialsNCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT05143840 2026-01-22
ALERTCML
Augusta University
Phase 2 Recruiting
NCT03760523 2026-01-07
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT06138587 2026-01-02
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07292272 2025-12-26
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
University of Nebraska
Phase 2 Not yet recruiting
NCT05194397 2025-12-04
IAMFIT
Children's Hospital of Philadelphia
Phase 2 Recruiting
NCT06001788 2025-12-03
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06235801 2025-11-19
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT04260022 2025-11-05
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT01760655 2025-10-30
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT03779854 2025-10-15
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT06501196 2025-09-24
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Phase 1 Recruiting
NCT05871008 2025-09-15
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
Phase NA Active not recruiting
NCT05805605 2025-07-01
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT06130579 2025-06-03
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Peking University People's Hospital
Phase 2 Recruiting
NCT04789655 2025-05-31
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 1 Terminated
NCT04996875 2025-05-30
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT05458258 2025-04-30
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
University of Chicago
Completed
NCT04628338 2025-04-29
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT06537726 2025-04-10
REDEFINE
University of Zurich
Recruiting
NCT06904859 2025-04-01
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Shenzhen University General Hospital
Phase EARLY_PHASE1 Completed
NCT05282459 2025-03-20
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Phase 1/2 Completed
NCT01050036 2025-03-17
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia
Asan Medical Center
Phase NA Completed
NCT04310592 2024-12-12
CYNK001AML01
Celularity Incorporated
Phase 1 Terminated
NCT06643962 2024-11-12
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
Affiliated Hospital of Nantong University
Phase NA Recruiting
NCT04714372 2024-10-24
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT06369662 2024-10-16
CD155 Expression in Acute Myeloid Leukemia
Assiut University
Completed
NCT06512610 2024-07-22
ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML
Centre Hospitalier Universitaire de Nice
Not yet recruiting
NCT03176277 2024-07-15
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co. Ltd
Phase 1/2 Terminated
NCT05309018 2024-05-23
LAMIPA
Centre Hospitalier Régional Metz-Thionville
Withdrawn
NCT05963061 2024-04-09
Chronic Myeloid Leukemia (CML) Real-Life Database
University Hospital, Clermont-Ferrand
Recruiting
NCT02455024 2024-04-04
OMNI
Takeda
Terminated
NCT03613727 2023-11-07
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Virginia Commonwealth University
Phase 2 Completed
NCT02916979 2023-10-18
FluBuATG
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT04965649 2023-08-30
TIPHI
Centre Hospitalier Universitaire de NÄ«mes
Unknown
NCT02203773 2023-05-16
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 1 Terminated
NCT04265963 2023-04-18
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04272125 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05787951 2023-03-28
Frequency and Risk Factors of Acute Myeloid Leukemia
Assiut University
Unknown
NCT04748848 2023-03-02
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Celgene
Phase 1 Terminated
NCT00887926 2022-12-22
Study of IMC-EB10 in Participant With Leukemia
Eli Lilly and Company
Phase 1 Terminated
NCT02287233 2022-08-29
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
AbbVie
Phase 1/2 Completed
NCT04406207 2022-08-22
ERVAL
Hospices Civils de Lyon
Withdrawn